Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS and haemophilia.

A L Bloom

    Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Most patients with hemophilia A treated with commercial factor VIII concentrates are infected with the AIDS virus (LAV/HTLV-III). However, the outlook for uninfected hemophiliacs regarding AIDS is now good due to improved treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Changes in Blood After Using an Extracorporeal Circulation.

    British medical journal·2010
    Same author

    Refining and optimization in multilayers.

    Applied optics·2010
    Same author

    Far-field pattern of gas lasers operated in the lowest order gaussian transverse mode.

    Applied optics·2010
    Same author

    Gas lasers.

    Applied optics·2010
    Same author

    Pressure shifts in a stabilized single wavelength helium-neon laser.

    Applied optics·2010
    Same author

    Orthognathic surgery in a patient with Noonan's syndrome.

    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons·1994

    Area of Science:

    • Hematology
    • Virology
    • Immunology

    Background:

    • High seropositivity rates for the AIDS virus (LAV/HTLV-III) observed in hemophilia A patients treated with commercial factor VIII concentrates.
    • Concerns regarding potential immunosuppressive agents in factor VIII concentrates and their link to LAV infection.
    • Lower incidence of AIDS, immune defects, and seropositivity in hemophilia B patients compared to hemophilia A.

    Purpose of the Study:

    • To assess the prevalence of overt AIDS and LAV/HTLV-III seropositivity in hemophilia A patients in the USA and UK.
    • To investigate factors contributing to LAV infection and immune defects in hemophilia patients.
    • To review diagnostic, social, and counseling challenges for infected patients and evaluate treatment strategies.

    Main Methods:

    Related Experiment Videos

  • Analysis of seropositivity rates for LAV/HTLV-III in hemophilia A and B patients based on treatment with commercial versus volunteer-derived blood products.
  • Review of historical data on infection onset and progression to symptomatic AIDS.
  • Survey of diagnostic, social, and family issues, alongside assessment of anti-viral and immunotherapy prospects.

    • Main Results:

    • Up to 90% of hemophilia A patients treated with commercial factor VIII concentrates are seropositive for LAV/HTLV-III.
    • Infection with LAV/HTLV-III began around 1978 in the USA and 1980 in Europe.
    • Seropositivity and AIDS are less common in hemophilia B patients, even when treated with factor IX concentrates from paid donors.

    Conclusions:

    • The outlook for uninfected hemophiliacs regarding AIDS is now favorable.
    • Heat-treated factor concentrates and donor screening have improved treatment policies.
    • Further research is needed to understand the anomaly of lower AIDS incidence in hemophilia B.